JP2025512512A - コロナウイルス感染症の予防又は治療のための組成物 - Google Patents

コロナウイルス感染症の予防又は治療のための組成物 Download PDF

Info

Publication number
JP2025512512A
JP2025512512A JP2024560783A JP2024560783A JP2025512512A JP 2025512512 A JP2025512512 A JP 2025512512A JP 2024560783 A JP2024560783 A JP 2024560783A JP 2024560783 A JP2024560783 A JP 2024560783A JP 2025512512 A JP2025512512 A JP 2025512512A
Authority
JP
Japan
Prior art keywords
amino acid
protein
mucoadhesive
seq
chimeric protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512512A5 (https=
Inventor
チェン リュー，
ホンビン ジャン，
ジヨウ サイ，
ジユアン ヤン，
ジンユン チェン，
ジンバオ リュー，
グワンヤン ション，
ワーナー グリーン，
Original Assignee
インビジシールド テクノロジーズ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インビジシールド テクノロジーズ リミテッド filed Critical インビジシールド テクノロジーズ リミテッド
Publication of JP2025512512A publication Critical patent/JP2025512512A/ja
Publication of JP2025512512A5 publication Critical patent/JP2025512512A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024560783A 2022-04-14 2023-04-13 コロナウイルス感染症の予防又は治療のための組成物 Pending JP2025512512A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263331216P 2022-04-14 2022-04-14
US63/331,216 2022-04-14
US202263418570P 2022-10-23 2022-10-23
US63/418,570 2022-10-23
PCT/US2023/065732 WO2023201304A2 (en) 2022-04-14 2023-04-13 Compositions for preventing or treating coronavirus infections

Publications (2)

Publication Number Publication Date
JP2025512512A true JP2025512512A (ja) 2025-04-17
JP2025512512A5 JP2025512512A5 (https=) 2026-04-21

Family

ID=88330386

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560783A Pending JP2025512512A (ja) 2022-04-14 2023-04-13 コロナウイルス感染症の予防又は治療のための組成物

Country Status (5)

Country Link
US (1) US12460193B2 (https=)
EP (1) EP4507729A2 (https=)
JP (1) JP2025512512A (https=)
CA (1) CA3256035A1 (https=)
WO (1) WO2023201304A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4687969A1 (en) * 2023-04-05 2026-02-11 DIOSynVax Ltd Coronavirus vaccines inducing broad immunity against variants
CN117777309B (zh) * 2023-11-28 2024-10-18 北京吉诺卫生物科技有限公司 一种包括xbbbq11类抗体的融合蛋白构建体、制备方法及其在疫苗中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US20030224000A1 (en) 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
WO2008016729A1 (en) 2006-08-04 2008-02-07 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
RU2654567C2 (ru) 2011-10-11 2018-05-21 Дженентек, Инк. Улучшенная сборка биспецифических антител
WO2018140456A1 (en) 2017-01-24 2018-08-02 Northwestern University Active low molecular weight variants of angiotensin converting enzyme 2 (ace2)
WO2018148447A1 (en) 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor
JP2023512684A (ja) 2020-02-03 2023-03-28 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
JP2023519105A (ja) 2020-02-11 2023-05-10 ヴァンダービルト ユニバーシティ 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）に対するヒトモノクローナル抗体
TWI818236B (zh) 2020-02-19 2023-10-11 美商聯合生物醫學公司 用於檢測、預防和治療新型冠狀病毒(covid-19)疾病的設計胜肽及蛋白質
BR112022017048A2 (pt) 2020-02-26 2022-11-16 Vir Biotechnology Inc Anticorpos contra sars-cov-2 e métodos para usar os mesmos
MX2022011142A (es) 2020-03-09 2022-12-13 Abcellera Biologics Inc Anticuerpos anti-coronavirus y metodos de uso.
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
CN111303280B (zh) 2020-03-22 2022-01-07 中国人民解放军军事科学院军事医学研究院 高中和活性抗SARS-CoV-2全人源单克隆抗体及应用
AU2021244774A1 (en) * 2020-03-23 2022-09-29 Monash University Antisense oligomers for treatment of disease
WO2021195326A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
US20230122364A1 (en) 2020-03-27 2023-04-20 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
KR20250107297A (ko) 2020-04-02 2025-07-11 리제너론 파아마슈티컬스, 인크. 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
US20230158125A1 (en) 2020-04-20 2023-05-25 Sorrento Therapeutics, Inc. Pulmonary Administration of ACE2 Polypeptides
JP2023537470A (ja) * 2020-08-03 2023-09-01 ヤンセン バイオテツク，インコーポレーテツド ウイルス治療における多方向バイオ輸送のための材料及び方法
WO2022075667A1 (ko) * 2020-10-05 2022-04-14 한양대학교 산학협력단 안정화된 ace2 변이체, 이를 이용한 ace2-fc 융합단백질 및 covid-19 예방 또는 치료용 약학 조성물
EP4228697A4 (en) 2020-10-16 2025-01-01 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections

Also Published As

Publication number Publication date
US20250109390A1 (en) 2025-04-03
WO2023201304A3 (en) 2023-11-23
WO2023201304A2 (en) 2023-10-19
CA3256035A1 (en) 2023-10-19
US12460193B2 (en) 2025-11-04
EP4507729A2 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
JP7554837B2 (ja) 可溶性ａｃｅ２及び融合タンパク質、並びにその適用
US20230129210A1 (en) Binding proteins useful against ace2-targeted viruses
US12460193B2 (en) Compositions for preventing or treating coronavirus infections
US11440952B2 (en) Compositions for preventing or treating viral and other microbial infections
US20240400651A1 (en) Neutralizing monoclonal antibodies against covid-19
US12459988B2 (en) Chimeric protein comprising an anti-influenza virus antibody moiety and a mucoadhesive peptide fragment for preventing or treating influenza infections
TW202221024A (zh) 結合sars-cov-2 s蛋白之中和抗體
US20240398911A1 (en) Engineered receptors and monoclonal antibodies for cronaviruses and uses thereof
WO2024229151A2 (en) Multimeric coronavirus binding molecules and uses thereof
WO2026030503A2 (en) Compositions and methods for preventing the spread of viruses
RU2837537C1 (ru) Растворимый апф2, его слитый белок и способы их применения
HK40064110A (en) Compositions for preventing or treating viral and other microbial infections
HK40083738A (en) Soluble ace2 and fusion protein, and applications thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260413